Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical ...

Led by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Experimental Therapeutics Group, in collaboration with VHIO's Hereditary Cancer Genetics Group and the Medical Oncology ...

Why do humans spend a third of their lives sleeping? Why do animals sleep? Throughout evolution sleep has remained universal and essential to all organisms with a nervous system, including ...

Gene editing is revolutionizing the understanding of health and disease, providing researchers with vast opportunities to advance the development of novel treatment approaches. Traditionally, ...

Racial disparities in radium-223 treatment in a large real-world population. Assessing the real-world (RW) efficacy and toxicity of docetaxel (D) for the treatment of metastatic castrate sensitive ...

Use of soluble CD27 as a marker of disease burden and the effect of rituximab-induced IgM flare and plasmapheresis in patients with Waldenström’s macroglobulinemia No significant financial ...

WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated ...

Parkinson’s disease is a common and debilitating age-related neurodegenerative disease that is increasing rapidly in prevalence and is expected to affect 14 million people worldwide by 2040. The ...

Drawn to the potential for improved selectivity and safety profiles of PARP-1-specific inhibitors over their first-generation counterparts, Merck KGaA signed an exclusive, worldwide license deal with ...